Immunitybio Total Assets vs Asset Turnover Analysis

IBRX Stock  USD 5.10  0.06  1.19%   
Immunitybio financial indicator trend analysis is infinitely more than just investigating Immunitybio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunitybio is a good investment. Please check the relationship between Immunitybio Total Assets and its Asset Turnover accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Total Assets vs Asset Turnover

Total Assets vs Asset Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunitybio Total Assets account and Asset Turnover. At this time, the significance of the direction appears to have pay attention.
The correlation between Immunitybio's Total Assets and Asset Turnover is -0.77. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Immunitybio, assuming nothing else is changed. The correlation between historical values of Immunitybio's Total Assets and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Immunitybio are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Total Assets i.e., Immunitybio's Total Assets and Asset Turnover go up and down completely randomly.

Correlation Coefficient

-0.77
Relationship DirectionNegative 
Relationship StrengthWeak

Total Assets

Total assets refers to the total amount of Immunitybio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunitybio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.
Most indicators from Immunitybio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunitybio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.At this time, Immunitybio's Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 802.07 in 2024, whereas Selling General Administrative is likely to drop slightly above 91.7 M in 2024.
 2021 2023 2024 (projected)
Total Operating Expenses331.2M362.9M218.0M
Cost Of Revenue24.2M18.5M13.5M

Immunitybio fundamental ratios Correlations

0.70.730.53-0.380.71-0.820.61-0.750.640.750.880.420.930.230.760.580.690.810.680.710.950.450.570.70.63
0.70.80.73-0.910.91-0.570.97-0.960.80.810.76-0.160.520.050.980.870.970.930.980.950.570.60.720.950.83
0.730.80.7-0.640.81-0.720.83-0.840.860.520.81-0.110.530.280.740.590.760.830.750.750.580.590.380.780.72
0.530.730.7-0.560.64-0.430.8-0.620.880.370.64-0.140.350.00.670.30.750.580.60.650.40.980.450.510.42
-0.38-0.91-0.64-0.56-0.80.28-0.910.86-0.64-0.66-0.530.44-0.180.03-0.85-0.87-0.87-0.77-0.92-0.85-0.24-0.44-0.64-0.87-0.82
0.710.910.810.64-0.8-0.770.9-0.960.790.710.88-0.120.450.260.930.820.940.960.920.980.510.510.780.920.84
-0.82-0.57-0.72-0.430.28-0.77-0.530.72-0.6-0.52-0.87-0.27-0.65-0.45-0.64-0.49-0.62-0.81-0.57-0.69-0.69-0.32-0.57-0.65-0.58
0.610.970.830.8-0.910.9-0.53-0.930.860.650.75-0.230.380.040.920.780.960.880.930.920.440.680.660.890.81
-0.75-0.96-0.84-0.620.86-0.960.72-0.93-0.78-0.8-0.840.1-0.54-0.17-0.96-0.9-0.95-0.99-0.97-0.96-0.6-0.47-0.75-0.98-0.89
0.640.80.860.88-0.640.79-0.60.86-0.780.420.82-0.050.380.050.720.470.850.750.710.750.450.810.560.690.61
0.750.810.520.37-0.660.71-0.520.65-0.80.420.580.070.740.070.860.860.740.810.850.780.760.240.660.840.65
0.880.760.810.64-0.530.88-0.870.75-0.840.820.580.210.640.290.790.60.830.870.740.840.690.550.720.750.76
0.42-0.16-0.11-0.140.44-0.12-0.27-0.230.1-0.050.070.210.520.18-0.06-0.1-0.090.02-0.13-0.110.49-0.140.02-0.1-0.25
0.930.520.530.35-0.180.45-0.650.38-0.540.380.740.640.520.140.60.460.460.620.510.481.00.280.350.540.41
0.230.050.280.00.030.26-0.450.04-0.170.050.070.290.180.140.120.10.090.230.090.20.16-0.050.010.120.04
0.760.980.740.67-0.850.93-0.640.92-0.960.720.860.79-0.060.60.120.890.960.940.980.970.640.540.780.940.83
0.580.870.590.3-0.870.82-0.490.78-0.90.470.860.6-0.10.460.10.890.820.870.940.870.50.140.70.950.83
0.690.970.760.75-0.870.94-0.620.96-0.950.850.740.83-0.090.460.090.960.820.920.950.970.520.630.830.910.81
0.810.930.830.58-0.770.96-0.810.88-0.990.750.810.870.020.620.230.940.870.920.940.950.670.430.750.970.84
0.680.980.750.6-0.920.92-0.570.93-0.970.710.850.74-0.130.510.090.980.940.950.940.960.560.460.750.980.85
0.710.950.750.65-0.850.98-0.690.92-0.960.750.780.84-0.110.480.20.970.870.970.950.960.540.520.810.930.84
0.950.570.580.4-0.240.51-0.690.44-0.60.450.760.690.491.00.160.640.50.520.670.560.540.330.40.580.47
0.450.60.590.98-0.440.51-0.320.68-0.470.810.240.55-0.140.28-0.050.540.140.630.430.460.520.330.360.350.31
0.570.720.380.45-0.640.78-0.570.66-0.750.560.660.720.020.350.010.780.70.830.750.750.810.40.360.720.7
0.70.950.780.51-0.870.92-0.650.89-0.980.690.840.75-0.10.540.120.940.950.910.970.980.930.580.350.720.87
0.630.830.720.42-0.820.84-0.580.81-0.890.610.650.76-0.250.410.040.830.830.810.840.850.840.470.310.70.87
Click cells to compare fundamentals

Immunitybio Account Relationship Matchups

Immunitybio fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets143.1M221.4M468.9M362.4M504.5M288.0M
Short Long Term Debt Total14.8M275.5M645.7M723.8M726.7M763.1M
Other Current Liab5.8M51.6M52.3M45.3M43.8M25.3M
Total Current Liabilities11.6M68.1M369.0M500.9M58.3M108.2M
Total Stockholder Equity120.7M(119.8M)(242.2M)(447.3M)(587.0M)(557.6M)
Property Plant And Equipment Net72.2M90.7M119.2M189.4M182.7M191.8M
Net Debt(660K)240.6M464.6M619.1M461.3M484.3M
Retained Earnings(662.2M)(1.6B)(2.0B)(2.4B)(3.0B)(2.8B)
Accounts Payable1.7M11.5M11.4M21.0M9.2M7.2M
Cash15.5M34.9M181.1M104.6M265.5M278.7M
Non Current Assets Total87.4M109.7M134.6M221.8M210.4M115.9M
Non Currrent Assets Other(11.1M)3.3M7.2M6.6M9.7M15.6M
Cash And Short Term Investments51.7M96.1M317.1M107.2M266.5M159.3M
Net Receivables303K2.0M1.3M1.9M3.2M2.7M
Common Stock Total Equity10K11K40K42K48.3K50.7K
Liabilities And Stockholders Equity143.1M221.4M468.9M362.4M504.5M288.0M
Non Current Liabilities Total10.9M271.7M343.8M311.3M1.0B1.1B
Other Current Assets3.8M9.2M15.9M31.5M24.5M25.7M
Other Stockholder Equity783.0M1.5B1.7B1.9B2.4B2.5B
Total Liab22.4M339.9M712.8M812.2M1.1B1.1B
Property Plant And Equipment Gross72.2M67.4M172.2M258.7M267.0M280.4M
Total Current Assets55.8M111.7M334.3M140.6M294.1M172.1M
Accumulated Other Comprehensive Income(105K)122K4K183K10K10.5K
Intangible Assets12.1M1.5M1.4M20.0M17.1M17.9M
Common Stock10K38K40K42K67K70.4K
Short Term Investments36.1M61.1M136.0M2.5M1.0M958.5K
Other Assets1.07.6M6.4M6.6M7.6M4.4M
Capital Surpluse783.0M1.5B1.7B1.9B2.2B1.3B
Property Plant Equipment27.8M29.0M82.9M143.7M165.2M173.5M
Other Liab8.3M1.6M411K22.0M25.3M26.6M
Net Tangible Assets(118.6M)(236.5M)(243.6M)(467.3M)(420.6M)(399.6M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.